Aura Biosciences Approves Increase in Authorized Shares at Special Meeting

What Happened
Aura Biosciences, Inc. (AURA) announced that at its Special Meeting of Stockholders on August 5, 2026, shareholders approved an amendment to increase the company’s authorized common stock from 150,000,000 to 500,000,000 shares. The record date was June 12, 2026 (103,436,416 shares outstanding), and 89,490,726 shares were represented at the meeting, constituting a quorum. The vote on the charter amendment passed with 62,993,701 votes for, 26,496,186 against and 839 abstentions.

Key Details

• Special Meeting date: August 5, 2026; record date: June 12, 2026 (103,436,416 shares outstanding).
• Charter amendment approved to increase authorized common shares from 150,000,000 to 500,000,000. Vote: 62,993,701 For; 26,496,186 Against; 839 Abstain.
• Stock plan amendment approved: Amendment No. 1 to the 2021 Stock Option and Incentive Plan. Vote: 46,369,676 For; 27,372,773 Against; 819 Abstain; 15,747,458 Broker Non‑Votes.
• For more detail on the proposals, see the company’s Definitive Proxy Statement filed June 29, 2026.

Why It Matters
Increasing authorized shares gives Aura legal capacity to issue more shares in the future for purposes such as capital raises, equity compensation, or strategic transactions. That can provide flexibility for growth but also creates the potential for dilution of existing shareholders if the company issues new shares. Approval of the amendment to the 2021 Stock Option and Incentive Plan indicates the company can grant additional equity awards under that plan; investors should review the proxy/plan details to understand how many additional shares may be available and the potential dilution impact.